A Phase 1, Open-Label Fixed-Sequence 2-Period Study To Investigate The Effect Of Multiple Doses Of Rifampin On Palbociclib (PD-0332991) Pharmacokinetics In Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 22 Apr 2015
Price : $35 *
At a glance
- Drugs Palbociclib (Primary) ; Rifampicin
- Indications Breast cancer; Colorectal cancer; Glioblastoma; Liposarcoma; Mantle-cell lymphoma; Multiple myeloma; Solid tumours
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Pfizer
- 16 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov record.
- 16 Dec 2013 Planned End Date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.